Coinbase CEO’s Biotech Firm Gets $130M to Fight Aging With AI, Genomics
NewLimit’s Series B raise adds fuel to Silicon Valley’s growing obsession with anti-aging science and biohacking immortality.
Archive context
Older archive item. Useful for background and entity history, but not a fresh market-moving signal.
Why this matters
This cryptocurrency story adds another data point to the current market tape and is useful when read alongside nearby source coverage.
Original source
Read on DecryptRelated market context
Coinbase Unveils AiFi After $100M in x402 Transactions, Targeting AI Agent Payments
Key Takeaways: Coinbase has announced the launch of its financial infrastructure initiative, AiFi, centered on the new AI agent ec...
Ripple Confirms 75+ Speakers for Swell 2026, Expects 1,500+ Attendees
Ripple has expanded its Swell 2026 speaker lineup with executives from Robinhood, BNY, and Intercontinental Exchange as the compan...
Trump to meet Coinbase, Ripple and crypto leaders as CLARITY Act odds collapse to 10%
President Donald Trump and the heads of the SEC and CFTC are expected to meet crypto and prediction-market executives at the White...
$1.6T JGB Repo Market Gets Onchain Push in Major MUFG Blockchain Experiment
Key Takeaways: The four MUFG group companies have started a proof-of-concept of onchain Japanese Government Bond repo transactions...
Paul Tudor Jones' Firm Buys Back Into BlackRock Bitcoin ETF After a Year of Selling
The macro fund raised its iShares Bitcoin Trust stake 18.9% to 688,529 shares worth $22.9 million in Q2, while sharply cutting its...
XRP Price Prediction: Wells Fargo Disclosed Millions in XRP Holding
XRP price trades near $1.00, remaining near the key level that separates confidence from doubt for its prediction. That flatline h...